Publications

 

Peer reviewed 




1. Rayon-Estrada V., Harjanto D. , Hamilton C.E , Berchiche Y.A., Gantman E.C., Sakmar T.P., Bulloch K., Gagnidze K., Harroch S., McEwen B.S., and Papavasiliou F. N. Epitranscriptomic profiling across cell types reveals associations between APOBEC1-mediated RNA editing, gene expression outcomes, and cellular function. (2017) Proc Natl Acad Sci U S A. pii: 201714227. doi: 10.1073/pnas.1714227114. [Epub ahead of print]. https://www.ncbi.nlm.nih.gov/pubmed/29167373
 

2. Berchiche Y.A., Sakmar T.P. CXC Chemokine Receptor 3 Alternative Splice Variants Selectively Activate Different Signaling Pathways. (2016)  Molecular Pharmacology pii: mol.116.105502. [Epub ahead of print]. 
http://www.ncbi.nlm.nih.gov/pubmed/27512119



3. Berchiche Y.A., Gravel S., Pelletier M-E.,Ste-Onge G., Heveker N. Different effects of the different natural CCR2 ligands on β-arrestin recruitment, Gαi signalling and receptor internalization.(2011) Molecular Pharmacology 79(3):488-98.  http://www.ncbi.nlm.nih.gov/pubmed/21088225

 

4. Gravel S. Malouf C., Boulais P., Berchiche Y.A., Oishi S., Fujii N., Leduc R., Sinnett D., Heveker N. The Peptidomimetic CXCR4 antagonist TC14012 Recruits Beta-Arrestin to CXCR7-Roles of Receptor Domains.(2010) Journal of Biological Chemistry 285(49):37939-43. http://www.ncbi.nlm.nih.gov/pubmed/20956518

 

5. Kalatskaya I*, Berchiche Y.A.*, Gravel S, Limberg B. J., Rosenbaum J.S, Heveker N. AMD3100 is a CXCR7 Ligand with Allosteric Agonist Properties. (2009) Molecular Pharmacology 75:1-8. * Contributed equally to this work. http://www.ncbi.nlm.nih.gov/pubmed/19255243

 

6. Rafei M., Berchiche Y.A., Birman E., Boivin MN., Young Y.K., Wu J. H., Heveker N., Galipeau J. An Engineered GMCSF-CCL2 Fusokine is a Potent Inhibitor of CCR2-driven Inflammation as Demonstrated in a Murine Model of Inflammatory Arthritis. (2009) Journal of Immunology183(3):1759-66. http://www.ncbi.nlm.nih.gov/pubmed/19592643

 

7. Berchiche Y.A., Chow K.Y, Lagane B., Leduc M., Percherancier Y., Fujii N., Tamamura H., Bachelerie F., Heveker N. Direct Assessement of CXCR4 Mutant Conformations Reveals Complex Link between Receptor Structure and Galpha i Activation.(2007) Journal of Biological Chemistry 282, 5111-5115. http://www.ncbi.nlm.nih.gov/pubmed/17197449

 

8. Desjardins S., Berchiche Y.A., Haddad E., Heveker N. CXCR4 -Récepteur de chimiokine aux talents multiples.(2007) Médecine Sciences23(11):980-4. Review in French. http://www.ncbi.nlm.nih.gov/pubmed/18021711

 

9. Dulude D.,Berchiche Y.A., Gendron K., Brakier-Gingras L., Heveker N. Decreasing the frameshift efficiency translates into an equivalent reduction of the replication of the human immunodeficiency virus type 1. (2006) Virology Volume 5; 345(1):127-36. http://www.ncbi.nlm.nih.gov/pubmed/16256163

 

10. Percherancier Y., Berchiche Y.A., Slight I., Volkmer-Engert R., Tamamura H., Fujii N., Bouvier M., Heveker N. Bioluminescence Resonance Energy Transfer Reveals Ligand-Induced Conformational Changes in CXCR4 Homo- and Heterodimers. (2005) Journal of Biological Chemistry 280: 9895-9903. http://www.ncbi.nlm.nih.gov/pubmed/15632118

 

Op-ED

1.  Berchiche Y.A., Kobayashi M., Naik S., Schneider J. Crashing the Old Boy's Science Club. Live Science's Expert Voices : Op-Ed and Insights. (2014) The Rockefeller University. http://www.livescience.com/49198-ending-sexism-in-science.html